Few leaders grow with a company long enough to transform it. Fewer still lead its defining chapter. From Management Trainee to Managing Director, Shreehas Tambe’s journey at Biocon is a story shaped by science, scale and self-confidence. Nearly three decades ago, he joined Biocon as a young scientist driven by a belief that innovation must ultimately serve those who need it the most. Over the years, he helped scale businesses, build global manufacturing capability, and expand Biocon’s footprint—always anticipating what patients and healthcare systems would need next. That leadership came into sharp focus with the transformation of Biocon Biologics. As CEO and Managing Director of Biocon’s largest subsidiary, Shreehas played a pivotal role in the acquisition of Viatris global biosimilars business, and the architect who built it into a fully integrated company catapulting Biocon Biologics into the world’s Top 5 biosimilar companies, with a valuation of over ₹50,000 crores (USD 5.5 billion) in 3 years. Today, as he assumes charge as the CEO & Managing Director of Biocon Limited to lead our combined generics and biosimilars business, Shreehas stands at the helm of yet another transformation. The next chapter is to build a fully integrated global medicines company that will compete and win on leveraging technology, scale and reach. From MT to MD - this is leadership shaped over time, and built for what comes next.
About us
Biocon: Enhancing Global Healthcare Biocon Limited, publicly listed in 2004, is India's largest and fully-integrated, innovation-led biopharmaceutical company. It is an emerging global biopharmaceutical enterprise serving customers in over 120 countries. Driven by a vision to enhance global healthcare through innovative and affordable biopharmaceuticals, we have enabled access to advanced therapies for diseases that are chronic, where medical needs are largely unmet and treatment costs are high. The early anticipation of the increasing dominance of biologics in global development pipelines helped us to be ahead of the curve in crafting a differentiated product portfolio based on fermentation and recombinant technologies, which straddles fermentation-derived small molecules and biologics, both novel as well as biosimilars. The significant brand equity that we have built worldwide for our small molecule APIs across statins, immunosuppresants and other specialty products has made us a leading global supplier of these products. We have also built one of the largest and most diverse biosimilar pipelines, spanning insulins, monoclonal antibodies and other recombinant proteins that address critical chronic diseases such as diabetes, cancer and autoimmune disorders. Ranked among the Top 3 biosimilar players globally for rh-insulin and insulin glargine in volume terms, we are the first Indian company to launch a biosimilar in Japan with Insulin Glargine, which also has been approved for sale in EU and Australia. Our insulin products have made a difference to the lives of millions of people with diabetes across the globe. We now aim to provide our insulin products to ‘one in five’ people with diabetes in need of insulin-based therapy anywhere in the world within the next 10 years. We are also making a huge impact in the area of cancer care. Our biosimilar Trastuzumab, which was the first to be approved anywhere in the world and launched in India in 2014, has helped treat several thousand HER2-positive metastatic breast cancer patients. We are also the first company from India to get its biosimilar approved by the USFDA; Ogivri™, co-developed by Biocon and Mylan, is the first biosimilar Trastuzumab to be approved in the US. In addition to Trastuzumab, several of our biosimilar assets are on track for anticipated regulatory approvals in developed markets. We are also developing a pipeline of patented biologics to address global unmet medical needs. We have successfully launched a couple of novel biologics in India: Nimotuzumab for the treatment of head and neck cancer and Itolizumab to tackle psoriasis. Besides these, we have a basket of novel assets are under various stages of clinical development, including a high potential oral insulin. Through our subsidiary, Syngene, we offer a suite of integrated, end-to-end discovery and development services for novel molecular entities (NMEs) to the global life sciences sector. Ranked by the prestigious Science magazine among the Top 10 Best employers in the biotech industry, Biocon is passionately pursuing a mission to rationalize healthcare spends, enhance access to life-saving therapies and make a significant impact to global healthcare through ‘blockbuster’ drugs with the potential to benefit a billion patients.
- Website
-
http://www.biocon.com
External link for Biocon
- Industry
- Biotechnology Research
- Company size
- 5,001-10,000 employees
- Headquarters
- Bangalore, Karnataka
- Type
- Public Company
Locations
-
Primary
Get directions
Hosur Road, Electronics City
Bangalore, Karnataka 560100, IN
Employees at Biocon
Updates
-
At #Biocon, building an inclusive future goes beyond the workplace - it begins with empowering communities. As part of our #DEIB initiatives, over 20 #Bioconites came together to plan and execute a special outreach for female high school students. The day was filled with energy and learning - from an engaging self-defence session led by police constables, to a lively Zumba workout. More than just activities, it was about building confidence, promoting well-being, and creating a safe space for young minds to learn and thrive.
-
-
#DCATWeek2026 comes to a close! At #Biocon, we were happy to engage with global partners, exchange insights, and showcase our capabilities. The conversations this week reinforced the growing importance of collaboration and innovation in shaping the future of #healthcare. Thank you to everyone who connected with us - we look forward to building on these partnerships and driving impact together. #DCAT2026
-
-
Biocon reposted this
#ThrowbackThursday A wrap up to this special month dedicated to Celebrating and Empowering Women More! #International Women’s (Day) Month. Resharing a moment that continues to resonate well with most. I am revisiting a conversation from our Women’s Day event in the past where I had the opportunity to speak about something I deeply believe in 'Investing in Women is not just the 'Right thing to Do' Its a 'Smart thing to Do' With equal economic participation of women in workforce, we can accelerate both economic and social progress. What I shared then still holds true today. When women rise, entire societies rise. At Biocon Group, I remain proud of how we continue to break barriers, expand opportunities and nurture an environment where women can lead, thrive and shape meaningful change. It is equally encouraging to see more men step up as allies and partners in this shared journey. Empowering women creates a ripple effect that strengthens communities and builds a more equitable future. A panel discussion followed that brought together diverse and insightful voices from across functions, each adding depth and perspective to the conversation: Huge thanks to all the participants from #BioconBiologics Rhonda Duffy, Chief Operating Officer, Karthik S M, then Global Head of Talent Acquisition Kavitha Srinivasan Rao, then Project Group Leader, R & D Naga Sri Tharun Bhaviri, Assistant Manager, Manufacturing Operations Here is to continuing the spirit of International Women’s Day with a renewed commitment to equity, opportunity and progress for all. Listen here https://lnkd.in/gfZCcwE7 Biocon Biocon Biologics Biocon Group Biocon Academy Syngene International Limited #AccelerateGrowth #InvestInWomen #WomensMonth2026 #InclusiveGrowth #EquityInAction #WomensDay #Leadership #Equity #Empathy #EconomicGrowth #IWD #InternationalWomensDay Kavita Rao, Ph.D, MBA Karthik SM Rhonda Duffy
'International Women's Day Celebration' "Invest in Women & Accelerate Progress" Seema Ahuja
https://www.youtube.com/
-
Biocon reposted this
💫Happy Birthday, Kiran Mazumdar Shaw ✨ Some journeys are built on milestones… others on moments of trust, quiet strength, and a shared belief in what’s possible. Ours has been all of that and more. You haven’t just built an institution, you have created a legacy that lives on in people, in purpose, and in endless possibilities. With deep appreciation for a journey that will always remain special. Wishing you health, happiness, and many more years of inspiring impact. ❤️❤️❤️ March 23, 2026 #HappyBirthday #VisionaryLeader #Impact #Inspiration #Legacy #Leadership #purpose #passion #empathy #inclusion Biocon Group Biocon
-
-
Biocon reposted this
Some journeys are measured not in years, but in what they make possible. She believed that purpose could change the world and then she went ahead and proved it. She built a global enterprise, from the very beginning, for a healthy world — rooted not in ambition alone, but in the conviction that science must serve everyone. She ensured that affordable, life-saving medicines reached the people who needed them the most, not as a privilege, but as a right. Because breakthroughs change science, but access changes lives. She led not from a distance, but with empathy, with inclusion, and with the quiet strength that lifts everyone around her. Growth builds business. Hope nurtures lives. She never lost sight of either. Today, as we celebrate her 73rd birthday, we honour not just what she has built, but the values she built it on. Purpose. Excellence. Hope. Happy Birthday, Kiran Mazumdar Shaw. May you continue to inspire the world, one belief at a time. #HappyBirthday #KiranMazumdarShaw #SheBuilt #BioconGroup
-
#WomensDay2026 at #Biocon was all about coming together and creating moments of joy! From fun-filled games to other engaging activities, the day was a reminder of the vibrant spirit and camaraderie that our #women colleagues bring to the workplace everyday.
-
-
Biocon reposted this
Wishing everyone a very Happy Ugadi! 🌸 As the new year begins, may it bring you health, happiness, and success in all that lies ahead. #HappyUgadi #BioconGroup
-
-
#BioconAtDCAT: We look forward to engaging with you at #DCATWeek2026 to discuss #Biocon’s product portfolio, pipeline and services. To schedule a meeting, write to us at ContactUs.API@biocon.com, ContactUs.Formulations@biocon.com
-